نتایج جستجو برای: lrrk2 inhibitors

تعداد نتایج: 189958  

Journal: :Journal of Pharmacology and Experimental Therapeutics 2021

Gain-of-function mutations in leucine-rich kinase 2 (LRRK2) are associated with increased incidence of Parkinson disease (PD); thus, pharmacological inhibition LRRK2 activity is postulated as a disease-modifying treatment PD. Histomorphological changes lungs nonhuman primates (NHPs) treated small-molecule inhibitors have brought the safety this approach into question. Although it remains unclea...

Journal: :The Biochemical journal 2013
Evy Lobbestael Jing Zhao Iakov N Rudenko Aleksandra Beylina Fangye Gao Justin Wetter Monique Beullens Mathieu Bollen Mark R Cookson Veerle Baekelandt R Jeremy Nichols Jean-Marc Taymans

A cluster of phosphorylation sites in LRRK2 (leucine-rich repeat kinase 2), including Ser910, Ser935, Ser955 and Ser973, is important for PD (Parkinson's disease) pathogenesis as several PD-linked LRRK2 mutants are dephosphorylated at these sites. LRRK2 is also dephosphorylated in cells after pharmacological inhibition of its kinase activity, which is currently proposed as a strategy for diseas...

Journal: :The Journal of neuroscience : the official journal of the Society for Neuroscience 2012
Yulan Xiong Changqing Yuan Rong Chen Ted M Dawson Valina L Dawson

Both sporadic and autosomal dominant forms of Parkinson's disease (PD) have been causally linked to mutations in leucine-rich repeat kinase 2 (LRRK2), a large protein with multiple domains. The kinase domain plays an important role in LRRK2-mediated toxicity. Although a number of investigations have focused on LRRK2 kinase activity, less is known about the GTPase function of LRRK2. The activity...

Journal: :Human molecular genetics 2013
Kyle B Fraser Mark S Moehle João P L Daher Philip J Webber Jeri Y Williams Carrie A Stewart Talene A Yacoubian Rita M Cowell Terje Dokland Tong Ye Dongquan Chen Gene P Siegal Robert A Galemmo Elpida Tsika Darren J Moore David G Standaert Kyoko Kojima James A Mobley Andrew B West

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset Parkinson's disease (PD). Emerging evidence suggests a role for LRRK2 in the endocytic pathway. Here, we show that LRRK2 is released in extracellular microvesicles (i.e. exosomes) from cells that natively express LRRK2. LRRK2 localizes to collecting duct epithelial cells in the kidney that actively secrete exosomes into...

2017
Zohreh Hosseinzadeh Yogesh Singh Derya R. Shimshek Herman van der Putten Carsten A. Wagner Florian Lang

Leucine-rich repeat kinase 2 (Lrrk2) has been implicated in the pathophysiology of Parkinson's disease. Lrrk2 is expressed in diverse cells including neurons and dendritic cells (DCs). In DCs Lrrk2 was shown to up-regulate Na+/Ca2+-exchanger activity. The elimination of Ca2+ by Na+/Ca2+ -exchangers requires maintenance of the Na+ gradient by the Na+/K+ -ATPase. The present study thus explored w...

Journal: :The Journal of neuroscience : the official journal of the Society for Neuroscience 2010
Emma Deas Laura Dunn

Editor's Note: These short, critical reviews of recent papers in the Journal, written exclusively by graduate students or postdoctoral fellows, are intended to summarize the important findings of the paper and provide additional insight and commentary. For more information on the format and purpose of the Journal Club, please see Review of Ng et al. Parkinson's disease (PD) is the second most c...

2017
Shijie Wang Zhiyong Liu Tao Ye Omar S. Mabrouk Tyler Maltbie Jan Aasly Andrew B. West

Missense mutations in the leucine-rich repeat kinase 2 (LRRK2) gene can cause late-onset Parkinson disease (PD). LRRK2 mutations increase LRRK2 kinase activities that may increase levels of LRRK2 autophosphorylation at serine 1292 (pS1292) and neurotoxicity in model systems. pS1292-LRRK2 protein can be packaged into exosomes and measured in biobanked urine. Herein we provide evidence that pS129...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید